Our study cohort was diagnosed with breast cancer between 1991 and 2000, and did not receive current standard of care: women with Her2+ tumors did not receive adjuvant trastuzumab, few postmenopausal women received adjuvant aromatase inhibitors. Here, ERBB2 is linked to breast carcinoma.